- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06328660
Refitting Multifocal Contact Lens Wearers With a Different Multifocal Contact Lens
March 18, 2024 updated by: Coopervision, Inc.
Refitting Biofinity Multifocal Contact Lens Wearer With MyDay Multifocal Contact Lenses
The purpose of this study is to compare ease of handling and vision acuity of two multifocal contact lenses to correct presbyopia that are currently CE marked and on the UK market.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an interventional, prospective, open label, sequential design study.
Participants will wear each study contact lens on a daily disposable wearing modality for 14 ± 3 days and attend the clinic for a total of three study visits.
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, SW1E6AU
- Ocular Technology Group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 40 years and older;
- Current multifocal contact lens wearer (other than MyDay® multifocal but can include Biofinity® multifocal);
Spectacle refraction:
- Distance: Sphere: -6.00D to + 4.00D
- Astigmatism: 0.00D to -0.75D
- Near Addition: Low +0.75D to +1.25D; Medium +1.50D and +1.75D; High +2.00D to +2.50D
- Best corrected visual acuity of at least 20/25 in each eye. - The prospective participants will be given a Participant Information Sheet to read and an Informed Consent Form to sign prior to any evaluation.
Exclusion Criteria:
To be eligible as a participant, each candidate shall be free of any ocular or medical condition that may affect the results of this study. The following are specific criteria that exclude a candidate from enrolment in this study:
- Acute and subacute inflammation or infection of the anterior chamber of the eye.
- Any eye disease, injury or abnormality that affects the cornea, conjunctiva or eyelids that would contraindicate contact lens wear;
- Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic
- Severe insufficiency of lacrimal secretion (dry eyes).
- Any systemic disease that may affect the eye or may be exaggerated by wearing contact lenses (e.g. acne and eczema).
- Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions
- Any active corneal infection (bacterial, fungal, protozoal or viral).
- Newly prescribed (within the past 30 days) use of some systemic medications (such as antihistamines, decongestants, diuretics, muscle relaxants, tranquilizers, stimulants, anti-depressants, anti-psychotics, oral contraceptives) or new prescription eyedrops which is not rewetting/lubricating eyedrops for which contact lens wear could be contraindicated as determined by the investigator;
- Monocular participants (only one eye with functional vision) or participants fit with only one contact lens;
- Subjects with slit lamp findings greater than grade 1 (e.g. edema, infiltrates, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival, anterior segment inflammation) as per ISO 11980, any previous history or signs of a contact lens related corneal inflammatory event (past corneal ulcers), or any other ocular abnormality that may contraindicate contact lens wear at the enrolment visit;
- History of corneal refractive surgery
- Enrolment of the family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.
- Current wearer of the test contact lens, MyDay® Multifocal.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lens 1
All participants will wear Lens 1 for 14 ± 3 days (Period 1)
|
Frequent replacement silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
|
Experimental: Lens 2
All participants will wear Lens 2 for 14 ± 3 days (Period 2)
|
Daily disposable silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Lens Handling
Time Frame: 1 week
|
The ease of contact lens insertion and removal over the week preceding the follow-up visit measured on a 100-point visual analog scale, where 0=Very difficult, Painful and 100=Very easy, Can't feel the lenses
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall logMAR Visual Acuity
Time Frame: 14 days
|
The mean logMAR visual acuity calculated as the mean of distance, intermediate, and near logMAR visual acuities.
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 15, 2024
Primary Completion (Estimated)
June 18, 2024
Study Completion (Estimated)
June 18, 2024
Study Registration Dates
First Submitted
March 12, 2024
First Submitted That Met QC Criteria
March 18, 2024
First Posted (Actual)
March 25, 2024
Study Record Updates
Last Update Posted (Actual)
March 25, 2024
Last Update Submitted That Met QC Criteria
March 18, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EX-MKTG-155
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presbyopia
-
Johnson & Johnson Vision Care, Inc.CompletedPresbyopia CorrectionUnited Kingdom
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
Lee, Steven, M.D.CompletedMyopia, | Hyperopia, | Astigmatism, | Presbyopia, | Eye Strain,
-
Allotex, Inc.RecruitingPresbyopiaCzechia, Ireland, Turkey, United Kingdom
-
Coopervision, Inc.Centre for Ocular Research & Education, CanadaRecruitingPresbyopiaUnited States, Canada
-
Optall VisionRecruiting
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.LENZ Therapeutics, IncCompleted
-
Allotex, Inc.TerminatedPresbyopiaBelgium, Ireland, United Kingdom
-
Coopervision, Inc.CORECompletedPresbyopiaUnited States, Canada
Clinical Trials on Lens 1
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Coopervision, Inc.Completed
-
Coopervision, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Aier School of Ophthalmology, Central South UniversityUnknown
-
Johnson & Johnson Vision Care, Inc.Completed
-
Aston UniversityBirmingham Women's and Children's NHS Foundation TrustRecruitingReflex Epilepsy, Photosensitive | EyeglassesUnited Kingdom
-
Coopervision, Inc.CompletedMyopiaUnited States
-
Coopervision, Inc.Completed